XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Provided By GlobeNewswire
Last update: Dec 2, 2024
Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets
Read more at globenewswire.comNASDAQ:XOMA (9/12/2025, 8:26:32 PM)
37.42
-0.3 (-0.8%)
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
NASDAQ:XOMAP (9/12/2025, 8:26:32 PM)
26.228
-0.47 (-1.77%)
XOMA ROYALTY CORP - XOMA 8 3/8 PERP
NASDAQ:XOMAO (9/12/2025, 8:26:32 PM)
25.4701
-0.07 (-0.28%)
Find more stocks in the Stock Screener
